Brief Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Jul 21, 2012; 18(27): 3617-3622
Published online Jul 21, 2012. doi: 10.3748/wjg.v18.i27.3617
Figure 2
Figure 2 Levels of hepatitis B surface antigen and hepatitis B e antigen following different treatments of HepG2. 2.15 cells. Sequential treatment reduced the levels of hepatitis B surface antigen (HBsAg) (A) and hepatitis B e antigen (HBeAg) (B) most strongly at 16 d in the treatment period. aP < 0.05 vs control group, cP < 0.05 vs lamivudine group, eP < 0.05 vs cytokine group.